Application of Genetic-Engineering Biological Therapy in Rheumatoid Arthritis Patients in the Republic of KazakhstanMaral Nogayeva
Department of outpatient treatment, Kazakh National Medical University named after S. D. Asfendiyarov, Abay st 87, Almaty, Kazakhstan.
Corresponding Author E-mail: firstname.lastname@example.org
Abstract: The purpose of this paper is to conduct a clinical-laboratory and radiological evaluation of the combined administration of infliximab and methotrexate to rheumatoid arthritis patients. The research is based on a retrospective analysis of medical records of inpatients, who underwent treatment at the S.D. Asfendiyarov Kazakh National Medical University Department of Ambulatory-Out-Patient Therapy and the city rheumatologic centre (CRC) of Almaty. The main group was injected with infliximab and methotrexate, while the control group – with methotrexate as background therapy. The groups were comparable in terms of age-related, gender, and clinical-laboratory indicators. The research used DAS28 and its standard components and the Larsen index. It was established that the aggregate clinical-laboratory effectiveness of the combined background therapy is determined by a significantly greater reduction of the DAS28 (p<0.05), and a high probability of transition from the average and high to the low level of disease activity (OR – 4.90 [2.47-9.75]), compared to monotherapy. The study proved the significant effect of infliximab and methotrexate on radiological signs of osseous lesion – erosion count (p<0.05) and Larsen index (p<0.05), and the high probability of prevention of osteochondral progression, compared to a mono-component background therapy (OR – 2.66 [1.42-5.01]). The combined administration of infliximab and methotrexate for rheumatoid arthritis patients has greater clinical-laboratory and radiological effectiveness, compared to background monotherapy.Keywords: DAS28; EULAR; larsen Index; Methotrexate; Osteochondral Destruction Back to TOC